Bassem is Chief Executive Officer
Bassem was appointed CEO in 2019 after joining TFS in 2017 to serve as Chief Medical Officer and Executive Vice President of Clinical Development Services, TFS’ largest business area. As CEO, he is responsible for leading the company’s global workforce of 700 employees across 40 countries and for driving TFS’ growth strategy to support our customers and bring treatments to patients faster.
Bassem is a hemato-oncologist and pharmaceutical consultant by training with more than 12 years’ experience in the drug development and life sciences industry. His contributions to TFS have been strategic, helping to position the company for future growth and secure new partnerships, as well as scientific, continuing to consult with biotech and pharmaceutical clients on product development and market approval.
Prior to joining TFS, Bassem held senior leadership positions and played an integral part in the success of large- and mid-size contract research organizations (CROs) including ICON, PRA Health Sciences, and Premier Research.
Bassem holds an MD from the Lebanese University and an MFPM and CCT in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians in the UK.